Henrik Zetterberg

Henrik Zetterberg, a leading expert in Alzheimer’s research from the University of Gothenburg, discusses the recent breakthroughs in understanding and treating the disease. He highlights the growing acceptance of the amyloid cascade hypothesis and the development of FDA-approved drugs. Zetterberg elaborates on exciting studies involving biomarker-positive individuals without symptoms, questioning if early amyloid removal can slow down disease progression. He advocates for quicker approvals of new treatments to enhance patient care.